RAZADYNE ER

LOE Approaching

galantamine hydrobromide

NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3

Mechanism of Action

Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a…

Clinical Trials (3)

NCT00297362N/ACompleted

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Started Jun 2004
344 enrolled
Alzheimer Disease
NCT00216593Phase 3Completed

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Started Dec 2003
415 enrolled
DementiaAlzheimer Disease
NCT00077727Phase 3Completed

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Started Mar 2003
107 enrolled
Schizophrenia